Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The pneumococcal conjugate vaccine.

R M Jacobson1, G A Poland

  • 1Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA. jacobson.robert@mayo.edu

Minerva Pediatrica
|July 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to: Use of statins in patients with COVID-19.

QJM : monthly journal of the Association of Physicians·2020
Same author

Does apolipoprotein E genotype predict COVID-19 severity?

QJM : monthly journal of the Association of Physicians·2020
Same author

Response to: Cardiac drugs and outcome in COVID-19.

QJM : monthly journal of the Association of Physicians·2020
Same author

Are certain drugs associated with enhanced mortality in COVID-19?

QJM : monthly journal of the Association of Physicians·2020
Same author

Knowledge gaps persist and hinder progress in eliminating mumps.

Vaccine·2018
Same author

Personalized vaccinology: A review.

Vaccine·2017

Pneumococcal conjugate vaccines effectively protect young children against invasive bacterial infections like pneumonia and meningitis. This vaccine is recommended for all infants and high-risk children under five, with mild side effects reported.

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • Streptococcus pneumoniae causes significant childhood illnesses, including otitis media, sinusitis, pneumonia, bacteremia, and meningitis.
  • Antibiotic resistance in S. pneumoniae is a growing concern.
  • Infants under two respond poorly to polysaccharide vaccines due to immature immune systems.

Purpose of the Study:

  • To evaluate the immunogenicity and efficacy of a heptavalent pneumococcal conjugate vaccine (Prevnar) in infants and children.
  • To assess the vaccine's effectiveness in preventing invasive pneumococcal disease, pneumonia, and otitis media.

Main Methods:

  • Infants received three doses at 2, 4, and 6 months, with a booster at 12-15 months.
  • Immunogenicity was assessed by antibody response in infants, including those with sickle cell disease and HIV.

Related Experiment Videos

  • An efficacy trial involved nearly 38,000 subjects.

    • Main Results:

    • Vaccination induced antibodies to all 7 serotypes, with an amnestic response upon booster doses.
    • The vaccine demonstrated effectiveness in healthy children against invasive pneumococcal disease, pneumonia, and otitis media.
    • Successful immune responses were observed in children with sickle cell disease and HIV.

    Conclusions:

    • The pneumococcal conjugate vaccine is immunogenic and effective in preventing pneumococcal infections in children.
    • The US ACIP recommends routine vaccination for all infants and high-risk children up to 59 months.
    • Common adverse events include local reactions and fever, which are generally mild and transient.